地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:17754422825
传真:15172469628
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Crystal Positioning Systems (CPS)品牌。
Crystal Positioning Systems (CPS)是专业蛋白结晶设备生厂商,包括:Puck 样品槽、液氮箱、运输箱、样品储存和转移用的工具。Crystal Positioning Systems (CPS) 是一家专注于为X射线晶体学和结构生物学领域提供高精度样品定位和自动化解决方案的公司,CPS 的产品旨在帮助科学家在蛋白质晶体学、材料科学和其他相关领域的研究中,实现更高效、更精确的样品定位和数据收集。公司以其创新的技术、高质量的产品和对客户需求的深刻理解而闻名。核心业务领域:
(1)高精度样品定位系统:CPS 提供用于X射线衍射仪的高精度样品定位系统,支持蛋白质晶体和小分子晶体的精确对准。这些系统能够显著提高数据收集的效率和准确性。
(2)自动化晶体成像系统:公司开发了自动化晶体成像系统,用于实时监测晶体生长过程,帮助科学家优化晶体生长条件。这些系统通常与X射线衍射仪集成,支持从晶体生长到数据收集的全流程自动化。
(3)机器人样品处理系统:CPS 提供机器人样品处理系统,用于高通量晶体筛选和数据收集。这些系统能够自动处理大量样品,显著提高实验效率。
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Crystal Positioning Systems (CPS)品牌"> 艾美捷科技代理Crystal Positioning Systems (CPS)品牌

艾美捷科技代理Serumwerk Bernburg AG品牌。
Serumwerk Bernburg AG在医药产品、医疗器械和活性药物成分的开发和生产领域,已逾60多年。Serumwerk Bernburg AG为广大科研和临床工作者提供一系列碘化物的密度梯度分离液包括:即用型、多功能型分离液。该系列产品不仅可以分离多种种属如人、灵长类、啮齿类、兔、反刍动物等来源的多种细胞、亚细胞器,而且可以分离纯化膜囊泡、病毒、蛋白质、核酸以及脂蛋白等物质。公司的产品符合美国FDA及获得欧洲cGMP标准,它们具有安全无毒、低渗透性和分离纯化效果好等特点。
<艾美捷科技代理Independent Forensics品牌全系列产品
Independent Forensics 是一家法医 DNA 实验室,提供 DNA 测试,致力于为犯罪实验室、医学遗传学和人类个体识别领域开发新颖、创新且可靠的产品和服务。IFI的研究与开发涵盖面向执法机构的新产品、用于高灵敏度遗传识别的先进技术,以及面向健康专业人士和公众的新型基因检测方法。

▍Independent Forensics产品线
● AMPLICON RX™ KITS:DNA-STR多重检测扩增后回收技术;
● 显微镜套装:专为手动或自动化精子搜寻与细胞分离定制的蔡司显微镜及成像系统,并包含SPERM HY-LITER™ 精细胞检测试剂盒。
● iPLEX STR 检测试剂盒:用于18个STR基因座及Amelogenin基因检测的多重STR试剂盒。
● ONE TOUCH™ 试剂盒:适用于:接触DNA、指纹、粘性介质及激光捕获显微切割样本。
● 快速斑迹识别试剂盒:RSID™系列专为快速、简便、可靠地检测法医实验室遇到的各种样本中的特定人体体液而设计。
● SPERM HY-LITER™ 精细胞检测试剂盒:专为性侵证据设计的完整荧光染色试剂盒。特异性强。灵敏度高。操作灵活。支持自动化。
▍Independent Forensics部分产品列表
| 分类 | 货号 | 产品描述 |
| AMPLICON™ Rx 试剂盒 | 5999 | Amplicon Rx™ 10 检测/试剂盒 - 1/2 尺寸试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6000 | Amplicon Rx™ 20 检测试剂盒/试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6001 | Amplicon Rx™ 40 检测试剂盒/试剂盒 - 大试剂盒 |
| iPlex STR™ | 6600 | 96 次反应 |
| iPlex STR™ | 6500 | 48 次反应 |
| iPlex STR™ | 6400 | 24 次反应 |
| iPlex STR™ | 6600-310 | 310 基质标准品 |
| iPlex STR™ | 6600-3100 | 其他尺寸标准 |
| iPlex STR™ | 6600-3130 | 其他尺寸标准 |
| iPlex STR™ | 6600-3500 | 其他尺寸标准 |
| iPlex STR™ | 6600-S400 | 其他尺寸标准 |
| iPlex STR™ | 6700-M1 | iPLEX-STR™ 迷你 1 |
| iPlex STR™ | 6700-M2 | iPLEX-STR™ 迷你 2 |
| iPlex STR™ | 6800-Y | iPLEX-STR™ Y |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-LIFT | 一键式 DNA 免费提升卡 - 15 个/包 |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-CK | 一键式采集现场试剂盒 - 20 个无 DNA 拭子 + NDLB 采集缓冲液 |
| RSID™ Saliva Lab Kits | 0130 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Saliva Lab Kits | 0130-LARGE | RSID SALIVA UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Saliva Lab Kits | 0100 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Semen Field Kits | 2000-SMALL | 5 份检测试剂盒/试剂盒(小号 - 不包括剪刀和证据信封) |
| RSID™ Semen Field Kits | 2000 | 5 包/套件(用于现场的完整套件) |
| RSID™ Semen Field Kits | Oct-00 | 10 个测试/套件(小版 - 不包括剪刀和证据信封) |
| RSID™ Semen Lab Kits | 0230 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Semen Lab Kits | 0230-LARGE | RSID SEMEN UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Semen Lab Kits | 0200 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Urine Lab Kits | 0400-05 | 5 次检测/试剂盒,含缓冲液 |
| RSID™ Urine Lab Kits | 0400-10 | 10 次检测/试剂盒,含缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8000 | SPERM HY-LITER™ 疏水笔,用于勾勒涂片载玻片的轮廓 |
| Sperm Hyliter™ Replacement & Accessories | 8005 | 用于医院涂片载玻片的垫圈,矩形载玻片架,12 个/包 |
| Sperm Hyliter™ Replacement & Accessories | 8010 | 精子 HY-L™ 染色阳性对照玻片(指定 HY-LITER、EXPRESS 或 PI 染色) |
| Sperm Hyliter™ Replacement & Accessories | 8020 | SPERM HY-LITER™ 洗涤缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8030 | SPERM HY-LITER™ 封片剂 |
| Sperm Hyliter™ Replacement & Accessories | 8040 | SPERM HY-LITER™ 固定剂 |
| Sperm Hyliter™ Replacement & Accessories | 8050 | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT |
| Sperm Hyliter™ Replacement & Accessories | 8050-INT | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT - 国际运输 |
| Sperm Hyliter™ Express | 7301-MINI | Mini SPERM HY-LITER™ 试剂,用于染色 13、11 mm 孔或 26、8 mm 孔 |
| Sperm Hyliter™ Express | 7301 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ Express | 7302 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ Express | 7303 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ Express | 7302-SOS | SPERM HY-LITER™ SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ Express | 7303P | SPERM HY-LITER™ EXPRESS 大号套件,带 DTT,可选择载玻片和储物盒 |
| Sperm Hyliter™ Microscopes | 10078 | SPERMCAM - 2/3“ CCD 彩色相机,带 SpermCapture 软件,需要支持 C 接口的显微镜 |
| Sperm Hyliter™ Microscopes | 27777 | SPERM HY-LITER™ aureka 细胞分离系统,带染色试剂盒包和现场培训 |
| Sperm Hyliter™ Microscopes | 37777 | SPERM HY-LITER™ LCM 精子搜索、解剖系统与染色套件包和现场培训 |
| Sperm Hyliter™ Microscopes | custom | 提供替换显微镜部件和附件 - 物镜、灯泡、电线、橡胶目镜杯、防尘罩等。 |
| Sperm Hyliter™ Microscope Slides | 9108-25 | 精子 HY-L™ 1 x 8 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9108-26 | SPERM HY-LITER™ 1 x 8 mm, 25 张载玻片/包 & 存储盒 |
| Sperm Hyliter™ Microscope Slides | 9111-25 | 精子 HY-LITER™ 1 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9111-26 | SPERM HY-LITER™ 1 x 11毫米,25张幻灯片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9211-25 | 精子 HY-LITER™ 2 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9211-26 | SPERM HY-LITER™ 2 x 11 mm, 25张载玻片/包&存储盒 |
| Sperm Hyliter™ Microscope Slides | 9408-25 | 精子 HY-L™ 4 x 8 毫米,25 张玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9408-26 | SPERM HY-LITER™ 4 x 8 mm,25 张载玻片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9000-25 | 精子 HY-LITER™ 24 x 60 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9000-26 | SPERM HY-LITER™ 24 x 60 mm, 25张载玻片/包&储存盒 |
| Sperm Hyliter™ Microscope Slides | 9999-00 | SPERM HY-LITER™ 定制设计的显微镜载玻片 |
| Sperm Hyliter™ PI | 7401 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ PI 试剂 |
| Sperm Hyliter™ PI | 7402 | 中等精子 HY-LITER™ PI 试剂,用于染色 50、11 mm 孔或 100、8 mm 孔 |
| Sperm Hyliter™ PI | 7403 | 大精子 HY-LITER™ PI 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ PI | 7402-SOS | SPERM HY-LITER™ PI SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ PI | 7403-SOS | SPERM HY-LITER™ SOS - 新型溶液染色试剂盒,带国际 DTT,染色 150 个样品 |
| Sperm Hyliter™ | 7126 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ | 7150 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ | 7250 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ | 7250P | SPERM HY-LITER™ 大号套件,带 DTT,150 个 1x11 mm 孔载玻片和储存盒 |
| RSID™ Urine Field Kits | 4000 | 尿液 5 次检测/试剂盒,含预装尿液缓冲液、拭子、水和移液管 |
| RSID™ Urine Field Kits | 4000-10 | 尿液 10 次检测/试剂盒(同上 - 不包括剪刀或证据信封) |

艾美捷科技代理DiscoverX 品牌。
DiscoverX 是一家专注于药物发现和生物分析的公司,提供创新的高通量筛选技术和生物分析工具,支持药物研发、毒理学研究和生物标志物发现。Eurofins DiscoverX® 是值得信赖的药物发现和开发产品解决方案供应商。作为 Eurofins Discovery 的产品部门,以及 Eurofins BioPharma 全球网络的一部分,DiscoverX 在过去二十年里通过为拯救生命的治疗药物的发现和开发做出贡献,这些药物使用了值得信赖和经过验证的细胞基检测产品,用于筛选和验证数十亿个数据点。DiscoverX 产品组合包括适合目的的解决方案,从即用型均质检测试剂盒、稳定的工程细胞系、膜准备、重组蛋白质/酶和合格试剂。
DiscoverX 主要产品和服务包括:
(1)高通量筛选平台:提供基于细胞和酶的高通量筛选平台,用于药物发现和毒性测试。
(2)生物分析工具:提供多种生物分析工具,如报告基因检测、细胞活性检测和蛋白质相互作用分析。
(3)定制服务:根据客户需求,提供定制化的高通量筛选和生物分析服务。
(4)技术咨询与支持:提供药物发现和生物分析相关的咨询和技术支持服务。
<艾美捷科技代理Imanis Life Sciences品牌全系列产品
Imanis Life Sciences是一家专注于再生医学、基因治疗、肿瘤学及溶瘤病毒疗法研究领域的生物技术公司。Imanis Life Sciences科研领域提供两大核心解决方案:溶瘤病毒治疗研究产品:供应用于溶瘤病毒疗法研究的专用病毒制剂;非侵入性影像检测试剂:提供适用于体外及体内研究的全系列试剂,包括报告基因细胞系、报告基因慢病毒载体及特异性抗体。Imanis Life Sciences公司的产品主要包括高品质报告基因细胞系、慢病毒载体及基因构建体、NIS与VSV特异性抗体以及全系列溶瘤病毒资源库。

▍Imanis Life Sciences产品线
● 报告基因慢病毒载体与质粒体系:提供全系列报告基因慢病毒载体及配套质粒解决方案。
即用型病毒载体:安全高效的即用颗粒,适用于原代细胞等难转染细胞类型的报告基因递送(无需额外处理);
病毒包装质粒系统:用于自主制备慢病毒载体颗粒的完整质粒体系。
● 稳定细胞系产品线:提供支持肿瘤学及免疫肿瘤学体内外研究的全系列稳定细胞系。
组成型报告基因细胞系(持续表达):搭载荧光素酶、荧光蛋白或NIS报告基因。应用于体外药物筛选 / 活体动物肿瘤动态监测
肿瘤抗原工程细胞系(靶标调控型):经基因编辑调控常见肿瘤相关抗原及治疗靶点表达水平,核心靶标:CD19、EGFR、Her2
● 溶瘤病毒资源库:提供涵盖即用型病毒储备的完整解决方案,全面助力溶瘤病毒疗法的体内外研究进程。
● 抗体:提供优质的NIS抗体产品,全面兼容免疫印迹(WB)、免疫组化(IHC)、免疫荧光(IF)、流式细胞术,同时推出多功能抗VSV(水泡性口炎病毒)抗体,覆盖WB/IHC/IF/ELISA/流式及VSV中和实验全平台。
▍Imanis Life Sciences部分产品列表
| 品名 | 规格 | 货号 |
| V-pNIS | 0.25 mL;1.0 mL | LV053S;LV053L |
| LV-Ub-humanNIS-P2A-Puro | 0.25 mL;1.0 mL | LV038S;LV038L |
| LV-PGK-humanNIS-P2A-Puro | 0.25 mL;1.0 mL | LV036S;LV036L |
| LV-humanNIS-P2A-Puro | 0.25 mL;1.0 mL | LV019S;LV019L |
| LV-humanNIS-IRES-Neo | 0.25 mL;1.0 mL | LV013S;LV013L |
| LV-humanNIS | 0.25 mL;1.0 mL | LV001S;LV001L |
| LV-EF1α-humanNIS-P2A-Puro | 0.25 mL;1.0 mL | LV037S;LV037L |
| LV-CAG-humanNIS-P2A-Puro | 0.25 mL;1.0 mL | LV042S;LV042L |
| LV-rhesusNIS-PGK-Puro | 0.25 mL;1.0 mL | LV018S;LV018L |
| LV-rhesusNIS | 0.25 mL;1.0 mL | LV017S;LV017L |
| LV-EF1α-rhesusNIS-PGK-Puro | 0.25 mL;1.0 mL | LV040S;LV040L |
| LV-mouseNIS-P2A-Neo | 0.25 mL;1.0 mL | LV025S;LV025L |
| LV-mouseNIS-PGK-Puro | 0.25 mL;1.0 mL | LV022S;LV022L |
| Anti-human NIS antibody SJ1 | 0.25 ml | REA004 |
| Monoclonal anti-human NIS antibody (affinity purified) | 100 ul | REA011 |
| Anti-human (KELE) NIS antibody (affinity purified) | 100 ul | REA010 |
| Anti-human (ETNL) NIS antibody (affinity purified) | 100 ul | REA009 |
| Anti-human NIS antibody clone VJ2 | 0.25mL | REA003 |
| Anti-human NIS antibody clone VJ1 | 0.25mL | REA002 |
| Anti-rat NIS antibody (affinity purified) | 100 ul | REA008 |
| Anti-VSV antibody | 0.25mL | REA005 |

艾美捷科技代理Abliance品牌全系列产品
Abliance是一家法国的抗体制造商和服务提供商,由专家组成的团队,在细胞培养、蛋白质工程和质量控制方面拥有深厚专业知识,专注为体外诊断(IVD)及科研领域提供高合规性抗体解决方案,满足研究和诊断工业市场的抗体需求。
▍Abliance公司产品提供丰富可选择的抗体库
| 多物种来源 | 多特异性靶点 | 多样标记方式 | 多级适用品质 |
| anti-human Ig | anti-IgG, IgM, IgA | fluorescent | globulins |
| anti-mouse and rabbit Ig | anti-IgGAM | enzymatic | affinity purified antibodies |
| anti-goat, bovine, dog Ig ... | anti-Fc and Fab fragments | biotin | Fab and F(ab')2 fragments |
● Abliance的二抗产品为多克隆抗体,通过使用人或动物免疫球蛋白对实验动物(兔、山羊或绵羊)进行高效免疫后获得。收集的免疫血清除含有目标特异性抗体外,还包含非特异性抗体及血清杂蛋白。
● Globulins:经过系列非特异性纯化步骤(脱脂处理→硫酸铵沉淀→透析)后获得球蛋白组分,此中间产物适用于免疫沉淀技术。
● Affinity purified antibodies:随后通过亲和层析对抗体进行纯化,从而确保高特异性。此外,抗鼠/兔IgG(H+L)二抗需在装有人源IgA/IgG/IgM的凝胶层析柱上进行系统化吸附处理,确保其与人源IgA/IgG/IgM无交叉反应。
● Fragments:Abliance提供经酶切获得的F(ab')₂和Fab片段,适用于免疫组化/细胞学检测及流式细胞术等场景。相较于含Fc区的完整抗体,这些片段能显著降低非特异性结合。其更小的分子量可增强细胞和组织渗透性。
● Labeled antibodies:Abliance供应多样标记物复合体:球蛋白组分、纯化抗体及Fab/F(ab')₂片段,可与荧光染料(异硫氰酸荧光素)、酶类(过氧化物酶、碱性磷酸酶、β-半乳糖苷酶、葡萄糖氧化酶)及生物素进行偶联。

▍Abliance部分产品列表
| 货号 | 品名 | 规格 | Host | Antigen |
| BI 1014 | Anti-Human IgGAM Globulin | 4mg/2ml | Goat | Human IgGAM |
| BI 1015 | Anti-Human IgG (H+L) Globulin | 4mg/2ml | Goat | Human IgG (H+L) |
| BI 1016 | Anti-Human IgA (alpha) Globulin | 4mg/2ml | Goat | Human IgA (alpha) |
| BI 1018 | Anti-Human IgG (gamma) Globulin | 4mg/2ml | Goat | Human IgG (gamma) |
| BI 1019 | Anti-Human IgM (µ) Globulin | 4mg/2ml | Goat | Human IgM (µ) |
| BI 1025 | Anti-Human albumin Globulin | 4mg/2ml | Goat | Human albumin |
| BI 3014 | Anti-Human IgGAM Fab | 2mg/1ml | Goat | Human IgGAM |
| BI 3015 | Anti-Human IgG (H+L) Fab | 2mg/1ml | Goat | Human IgG (H+L) |
| BI 3016 | Anti-Human IgA (alpha) Fab | 2mg/1ml | Goat | Human IgA (alpha) |
| BI 3018 | Anti-Human IgG (gamma) Fab | 2mg/1ml | Goat | Human IgG (gamma) |
| BI 3019 | Anti-Human IgM (µ) Fab Goat | 2mg/1ml | Goat | Human IgM (µ) |
| BI 3025 | Anti-Human albumin Fab | 2mg/1ml | Goat | Human albumin |
| BI 4015 | Anti-Human IgG (H+L) F(ab')2 | 2mg/1ml | Goat | Human IgG (H+L) |
| BI 4016 | Anti-Human IgA (alpha) F(ab')2 | 2mg/1ml | Goat | Human IgA (alpha) |
| BI 4018 | Anti-Human IgG (gamma) F(ab')2 | 2mg/1ml | Goat | Human IgG (gamma) |
| BI 4019 | Anti-Human IgM (µ) F(ab')2 | 2mg/1ml | Goat | Human IgM (µ) |
| BI 4025 | Anti-Human albumin F(ab')2 | 2mg/1ml | Goat | Human albumin |
| BI 3414 | Anti-Human IgGAM Fab HRP | 1ml | Goat | Human IgGAM |
| BI 3415 | Anti-Human IgG (H+L) Fab HRP | 1ml | Goat | Human IgG (H+L) |
| BI 3416 | Anti-Human IgA (alpha) Fab HRP | 1ml | Goat | Human IgA (alpha) |
| BI 3418 | Anti-Human IgG (gamma) Fab HRP | 1ml | Goat | Human IgG (gamma) |
| BI 3419 | Anti-Human IgM (µ) Fab HRP | 1ml | Goat | Human IgM (µ) |
| BI 3425 | Anti-Human albumin Fab HRP | 1ml | Goat | Human albumin |
| BI 4414 | Anti-Human IgGAM F(ab')2 HRP | 1ml | Goat | Human IgGAM |
| BI 4415 | Anti-Human IgG (H+L) F(ab')2 HRP | 1ml | Goat | Human IgG (H+L) |
| BI 4419 | Anti-Human IgM (µ) F(ab')2 HRP | 1ml | Goat | Human IgM (µ) |
| BI 4425 | Anti-Human albumin F(ab')2 HRP | 1ml | Goat | Human albumin |

艾美捷科技代理MACHEREY-NAGEL品牌。
德国MN(Macherey-Nagel)(简称MN)成立于1911年是一家历史悠久的全球知名企业,专注于实验室耗材、快速检测产品及分析技术的研发与生产。从1993年起,MN公司成功研发了各种核酸分子分离和蛋白纯化的试剂盒和耗材,包括质粒抽提、PCR产物纯化和胶回收、RNA纯化、基因组DNA抽提、病毒核酸纯化试剂盒,以及His/GST标签蛋白纯化柱等。其产品以高品质、创新性和可靠性著称,广泛应用于环境监测、食品检测、医疗诊断、制药及科研领域。
MN品牌以多样化的产品线和创新技术满足不同领域需求:
● 实验室耗材:
滤纸、色谱柱、固相萃取柱(SPE)、微孔滤膜等。
特色:高纯度材料、精准分离性能,适用于复杂样品前处理。
● 快速检测产品:
试纸、试剂盒(如水质检测盒、食品安全检测盒)。
优势:操作简便、快速出结果,适用于现场检测。
● 诊断与医疗产品:
血液检测试纸、尿液分析试纸等,被医院和实验室广泛采用。
● 环境监测解决方案:
针对水质、空气污染等开发的高灵敏度检测工具。
更多详情请咨询→

全国免费热线:400-6800-868
直拨专线:132-6921-9473
客服QQ一:17754422825;
客服QQ二:18771149750
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理MACHEREY-NAGEL(德国MN)品牌"> 艾美捷科技代理MACHEREY-NAGEL(德国MN)品牌

艾美捷科技代理Peptides.de品牌全系列产品
Peptides.de是一家专注于高质量肽产品生产的的德国企业。公司创立于2001年,总部位于德国赫尼希斯多夫。从单一肽到百万级肽库,从线性链到环状结构,从短肽到超长序列,从粗品到高纯精肽,从修饰化到标记化,从天然氨基酸到非天然变体,Peptides.de提供全维度肽与肽模拟物解决方案,覆盖新抗原筛选、过继性免疫治疗、T细胞刺激实验、表位作图、ELISpot检测、药物发现及芯片技术等核心领域。
Peptides.de公司不仅生产肽,还自主开发用于肽合成的核心设备——肽合成机器人。凭借其专利技术超声肽合成平台 (USPS®),团队能够在短时间高效生产数百种肽,并精准实现客户所需的各种修饰。

▍ReVacc Scientific公司产品
Peptides.de核心业务涵盖:目录肽现货供应、专属肽链定制合成、个性化肽池构建、高通量肽库开发、肽芯片制备服务、功能型修饰肽生产以及精密预分装服务。

▍Peptides.de部分产品列表
| 品名 | 货号 | 规格 |
| ADV hexon (HLA-B*35:01) | EP07882_1 | 1 mg;5 mg |
| ADV hexon 114 -124 (HLA-B*07:02) | EP07881_1 | 1 mg;5 mg |
| ADV hexon 37-45 (HLA-A*24:02) | EP07880_1 | 1 mg;5 mg |
| ADV hexon 886-894 (HLA-A*01:01) | EP10774_1 | 1 mg;5 mg |
| ADV Hexon 917-925 (HLA-A*02:01) | EP07914_1 | 1 mg;5 mg |
| BKV VP1 108-116 (HLA-A*02:01) | EP11456_1 | 1 mg;5 mg |
| BRLF1 109-117 (HLA-A*02:01) | EP11139_1 | 1 mg;5 mg |
| Chlamydia trachomatis MOMP 258-266 (HLA-A*02:01) | EP11114_1 | 1 mg;5 mg |
| EBNA 3a (596-604) | EP10789_1 | 1 mg;5 mg |
| EBNA-1 Protein (562-570) | EP04510_1 | 1 mg;5 mg |
| EBV BALF-4 276-284 (HLA-A*02:01) | EP11237_1 | 1 mg;5 mg |
| EBV BMLF-1 280-288 (HLA-A*02:01) | EP07604_1 | 1 mg;5 mg |
| EBV BMRF1 116-128 (HLA-B*07:02) | EP11138_1 | 1 mg;5 mg |
| EBV BMRF1 208-216 (HLA-A*02:01) | EP11127_1 | 1 mg;5 mg |
| EBV BRLF-1 148-156 (HLA-A*03:01) | EP11482_1 | 1 mg;5 mg |
| EBV BRLF1 101-109 (HLA-A*29:02) | EP11142_1 | 1 mg;5 mg |
| EBV BRLF1 134-142 (HLA-A*11:01) | EP11140_1 | 1 mg;5 mg |
| EBV BRLF1 28-37 (HLA-A*24:02) | EP11141_1 | 1 mg;5 mg |
| EBV BZLF-1 190-197 (HLA-B*08:01) | EP07899_1 | 1 mg;5 mg |
| EBV BZLF-1 54-64 (HLA-B*35:01) | EP11143_1 | 1 mg;5 mg |
| EBV BZLF-1 54-64 mutant (HLA-B*35:01) | EP11144_1 | 1 mg;5 mg |
| EBV BZLF1 44-52 (HLA-B*07:02) | EP11214_1 | 1 mg;5 mg |
| EBV EBNA 3A 246-253 (HLA-A*24:02) | EP11147_1 | 1 mg;5 mg |
| EBV EBNA 3B 399-408 (HLA-A*11:01) | EP11150_1 | 1 mg;5 mg |
<艾美捷科技代理Osenses品牌全系列产品
Osenses是一家私营生物技术公司,总部位于南澳大利亚州阿德莱德,设计和制造研究试剂和科学仪器,产品涵盖自噬、SLC和调节器、离子通道和泵、报告基因和标签、水螅蛋白、繁殖、细胞的、神经、微体、亚细胞标记物、毒素、免疫学、ABC运输商、G蛋白信号传导、癌症等多个研究领域相关的试剂,对人工智能辅助解决生物问题特别感兴趣。公司产品线包括TerraBodies™、AquaBodies™、AdaptoBodies™、组织学。

▍Osenses公司产品线
● TerraBodies™:其系列产品包括自噬、SLC 和调节器、离子通道和泵、报告基因和标签、水螅蛋白、繁殖、细胞、神经、微体、亚细胞标记物、毒素、免疫学、ABC 运输商、G蛋白信号传导、癌症等方面。
● AquaBodies™:Carp antibody to EGFP/GFP/Venus
● AdaptoBodies™:其系列产品包含兔防鼠适应体™、兔防豚鼠适应体™、兔防山羊适应体™等多种适应体产品。
● 组织学:自动灌装器和配件、DAB 套件、蛋白质印迹。
▍Osenses部分产品列表
<| 品名 | 货号 | 应用 | 规格 | 宿主 |
| Rabbit antibody to Beclin-1 | OSB00002W | WB, IHC, ELISA, FC | 100 ul | NZ white rabbit |
| Sheep antibody to ATG10 | OSA00002W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to MAP1LC3A | OSA00003W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to ATG4C | OSA00004W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to ATG3 | OSA00005W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to Beclin-1 | OSA00006W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to GABARAP | OSG00005W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to MAP1 LC3C | OSM00020W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to ATG7 | OSA00008W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to TMEM166 | OST00001W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to ULK1 (350-410) | OSU00001W | IHC, WB | 150 µl | Sheep |
| Sheep antibody to MAP1LC3C | OSM00021G | IHC, WB | 500 µg | Sheep |
| Sheep antibody to Beclin 1 | OSB00001G | IHC, WB | 500 µg | Sheep |
| Sheep antibody to TMEM166 | OST00002G | IHC, WB | 500 ug | Sheep |
| Sheep antibody to ATG10 | OSA00010G | IHC, WB | 500 µg | Sheep |
| Sheep antibody to ATG3 | OSA00011G | IHC, WB | 500 µg | Sheep |
| Sheep antibody to ATG7 | OSA00012G | IHC, WB | 500 ug | Sheep |
| Sheep antibody to ATG4C | OSA00013G | IHC, WB | 500 µg | Sheep |
| Sheep antibody to MAP1LC3A | OSM00022G | IHC, WB | 500 ug | Sheep |
| Sheep antibody to ULK1 (350-410) | OSU00002G | IHC, WB | 500 ug | Sheep |
| Rabbit antibody to GABARAP | OSG00009W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG9A | OSA00015W | IHC, WB | 150 ul | NZ white rabbit |
| Rabbit antibody to LC3 C | OSM00023W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to MAP1LC3A | OSM00024W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG10 | OSA00016W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG4C | OSA00017W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG3 | OSA00018W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG7 | OSA00019W | IHC, WB | 150 µl | NZ white rabbit |
| Sheep antibody to ATG5 | OSA00020W | IHC, WB | 150 µl | Sheep |
| Rabbit antibody to ATG5 | OSA00021W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG5 | OSA00030W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG4D | OSA00031W | IHC, WB | 150 µl | NZ white rabbit |
| Rabbit antibody to ATG4D (10-50) | OSA00032W | IHC, WB | 150 µl | NZ white rabbit |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:13212737804
邮箱:sales@amyjet.com
0.2155